. Tumours thus appear to become addicted to chaperones and can be treated by withdrawing the chaperoning power of HSP90 (Refs 1, 4, 5) . CDC37 interacts with a subset of client proteins within HSP90 complexes and has a specialized role as primary partner in kinome maintenance 2, 6, 7 . This specialized property of CDC37 fuels the acceleration of cell proliferation observed in cancer by promoting the activities of a broad array of protein kinases 2, 8, 9 . These include receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) and MET, non-receptor tyrosine kinases SRC and lymphocyte-specific protein tyrosine kinase (LCK), and intracellular serine/threonine kinases RAF1, KSR (also known as CNKSR1), AKT1, IKK (also known as CHUK), CDC2, CDK2 and CDK4.
A comprehensive list of CDC37 client kinases, including the ones listed above and others, can be found at the website of Didier Picard (see URL in Further information). The degree of dependency of the cancer cell kinome on CDC37 expression thus appears to be extensive and in a recent yeast screen at least 90% of the protein kinases examined required CDC37 for function 10 .
CDC37 promotes proliferation
The defining cellular role for CDC37, which becomes misappropriated in cancer, resides in its promotion of cell proliferation. Indeed this protein was first discovered in a yeast screen for cell division cycle proteins, hence its name 11 . Thus, when mammalian tissues undergo rapid proliferation during development, the normally scarce levels of CDC37 are rapidly expanded. Increased levels of HSP90-CDC37 complexes mediate the maturation and stabilization of protein kinases required for proliferation or perhaps for repeated rounds of kinase reactivation 7, 12, 13 . For instance, increased levels of CDC37 in vivo correlate with the upregulation of the G1-specific cyclin D1 in proliferating normal tissues 2 (cyclin D1 is the partner of CDK4). Increased CDC37 levels also mediate cancer cell growth, although the degree to which changes in CDC37 regulation in proliferating normal tissues resemble those in malignant tissues is not clear. The role of CDK4 as a key CDC37 client in cancer is compelling, although the much larger cast of oncogenic signalling molecules mentioned above also requires CDC37. Proliferating tumour cells may also have an expanded dependency on CDC37 due to the increased repertoire of overexpressed or mutated kinases that mediate their growth (in accordance with the 'addicted to chaperones' hypothesis) 1 . However, the degree to which CDC37 responds to the quality or quantity of clients in these contrasting proliferative states is yet to be determined.
The amplified levels of CDC37 in prostate cancer suggest that it may be of particular significance in this type of neoplasm 6, 14, 15 . Indeed, in recent immunohistological studies, CDC37 overexpression was found in 100% of neoplastic prostate tissue, compared with normal prostate 6 . Although the rationale for this is not certain, one rather compelling suggestion involves the role of CDC37 in androgen signalling, a key pathway in prostatic cell growth. The androgen receptor (AR) is a rare non-kinase CDC37 client 16 . Although HSP90 has a general role in maintaining the function of nuclear receptors, CDC37 specifically associates with AR, in contrast to closely related nuclear receptors including the glucocorticoid receptor (GR, also known as NR3C1) 16 . CDC37 associates with the ligand-binding domain of AR, permitting the structural changes that accompany ligand encounter, factor activation and cell proliferation.
CDC37-kinase interaction
Strategies for targeting CDC37 in cancer treatment will be aided by considering the biochemical and ultrastructural nature of the CDC37-client interaction. The two bestknown properties of CDC37 are its abilities to bind to clients and to associate with HSP90, functions that involve two major structural domains 7, 9, 10 (fIG. 1) . The kinase binding domain (amino acids (aa) 1-126 in the human protein) is the most highly conserved region among CDC37 homologues and contains several key residues whose mutation or deletion each alter kinase binding 9 . The residue with most regulatory significance is serine (S) 13, whose phosphorylation permits stable interaction of CDC37 with client kinases 17 . Abstract | CDC37 is a molecular chaperone that physically stabilizes the catalytic domains found in protein kinases and is therefore a wide-spectrum regulator of protein phosphorylation. It is also an overexpressed oncoprotein that mediates carcinogenesis by stabilizing the compromised structures of mutant and/or overexpressed oncogenic kinases. Recent work shows that such dependency of malignant cells on increased CDC37 expression is a vulnerability that can be targeted in cancer by agents that deplete or inhibit CDC37. CDC37 is thus a candidate for broad-spectrum molecular cancer therapy. In turn, the kinase that phosphorylates S13, casein kinase II, is in itself a CDC37 client, and mediates a positive feedback loop between the client kinase and CDC37 chaperoning 18 . A second region within CDC37 (aa 127-282) interacts with the amino-terminal ATPbinding domain of HSP90. This interaction is predicted not only to mediate recruitment of client kinases to HSP90 but also to regulate the HSP90 ATPase activity that is required for chaperone activity 9 . By contrast, the carboxy-terminal domain (aa 282-378) of CDC37 remains relatively uncharacterized. In both Saccha romyces cerevisiae and Schizosaccharomyces pombe, only the N-terminal 'client interface' domain is required to support growth, suggesting that HSP90 is dispensable for the growth-promoting functions of CDC37 (Refs 19, 20) . However, in mammalian cells the homologous N-terminal construct functions as a dominant-negative inhibitor of wild-type CDC37 and a growth antagonist in prostate carcinoma cells 15 . This of course does not rule out HSP90-independent actions of CDC37 but rather suggests a shift in emphasis towards HSP90-dependent interactions in mammalian cells. Such differences between these classes of eukaryote might reflect the rather meagre degree of sequence conservation, less than 20%, between the mammalian and yeast molecules and make inferences derived from yeast studies somewhat uncertain for prediction of CDC37 behaviour in cancer 9 . of particular note, the affinity of mammalian CDC37 for HSP90 exceeds that of the S. cerevisiae homologue by greater than tenfold 9 . Mammalian CDC37 in tumour cells might thus have an increased tendency to function within a ternary complex containing the client kinase and HSP90 (fIG. 1) , although independent functions for CDC37 cannot be ruled out.
Protein kinases in all cells become associated with CDC37 and HSP90 in a stepwise process based largely on the paradigm first established for GR folding and maturation 21 . Initial kinase folding involves association with the chaperones HSP70 and HSP40 followed by a series of ATP-fuelled steps that lead to assembly of a folding complex containing HSP90 and its cohorts, including CDC37 bound to the kinase 1,4 . The more stable clients then exit the CDC37-HSP90 complex, although particularly sensitive kinases bind persistently to the HSP90 complexes. Such unstable clients proliferate in tumour cell populations owing to competition and selection for cells expressing variant and super-abundant mutant kinase variants that mediate tumour progression 2 . Considering the interaction from the viewpoint of the kinase, both CDC37 and HSP90 bind directly to the catalytic domain 9 ( fIG. 1) . The conserved catalytic domain comprises two lobes separated by a deep ATP binding cleft. CDC37 associates with the N-terminal lobe whereas HSP90 interacts with both lobes 9, 22, 23 . The N-lobe is more loosely packed in terms of polypeptide chain folding and can thus constitute a hazard in terms of tendency to unfold, lose function and nucleate degradation cascades 22, 23 .
Each kinase-chaperone interaction shows characteristic properties despite the catalytic domain being the third most common in the human genome 24 . Indeed, owing to subtle differences in N-lobe structure, some kinases may need persistent interactions with HSP90 and CDC37 for function and stability 9 . other kinases may be stabilized by additional intramolecular domains and/or by regulatory partner proteins that bring stability along with substrate specificity 23 . For instance, CDK4 binds initially to HSP90 and CDC37 until encountering cyclin D1 and forming a CDK4-cyclin D1 complex sufficiently stable to be independent of further chaperone interaction 25 . other kinases such as the oncoprotein ERBB2 bind persistently to chaperone complexes even in the active form (reviewed in Ref. 9) . It is predicted that the proliferation of mutation-activated kinases in tumours leads to a greater dependency on CDC37 chaperoning. Indeed, individual kinase targets may undergo continuous evolution in terms of CDC37 dependency owing to the emergence of novel mutant forms.
Future approaches to individualized care might involve screening for the emergence of CDC37-dependent kinase mutants. Drugs that inhibit the ATPase activity of HSP90 further destabilize these quasi-stable clients 1 . This concept has been reaffirmed in studies with anticancer drugs that bind and stabilize the ATP binding groove of client kinases and are able to prevent their proteasomal degradation through HSP90 inhibition. Indeed, the exchange of ATP in activated kinases induces their destabilization and interaction with CDC37 and HSP90. Thus mutations that allow a kinase to develop 'fast' activity also result in the kinase becoming structurally 'loose, ' with CDC37 and HSP90 helping maintain this 'fast and loose' existence. . Understanding the dynamics of kinase-CDC37-HSP90 interaction might be of particular significance for prediction of kinases in cancer cells most adversely affected by HSP90 and/or CDC37 inhibition and facilitation of anti-CDC37 drug design (for a definitive review of CDC37 and protein kinase interactions see Ref. 9 ).
Targeting CDC37 in cancer As mentioned earlier, CDC37 is an overexpressed oncogene. Indeed, under forced CDC37 expression cells become transformed and proliferate, and tumours arise. when CDC37 is overexpressed along with the proto-oncogene MYC, the effects of both agents become amplified and more and larger tumours arise in transgenic mice 6, 14, 15 . Indeed, CDC37 levels are increased in many clinical cancers 6 . Although CDC37 may be regarded as a specialized partner of HSP90, dealing with structurally compromised kinase clients, it may also be a preferable target for cancer therapy. HSP90 is expressed with similar abundance in normal and malignant cells and includes among its clientele proteins required for the viability of normal cells 26 . In its favour as a therapeutic target, some studies indicate that tumour HSP90 is selectively vulnerable owing to the proliferation of its oncogenic clients and the formation of mature HSP90-clientco-chaperone complexes that bind HSP90 drugs with increased affinity 27 . However, this phenomenon is not universally observed 28 . CDC37, by contrast, is increased in proliferating tissues, and is heavily expressed in certain cancers including prostate carcinoma, anaplastic large cell lymphoma, acute myelocytic leukaemia, hepatocellular carcinoma and multiple myeloma [29] [30] [31] [32] . As most normal tissues do not proliferate or appear to require CDC37, a potential therapeutic window is available, which is not as obvious in the case of HSP90.
The mechanisms underlying increased CDC37 expression in malignant cells are not known. The CDC37 promoter contains multiple binding sites for the transcription factor MZF1, which is implicated in myeloid tumorigenesis, although evidence for a dynamic role in CDC37 expression is not available 33 . The 'addicted to chaperones' hypothesis might predict that chaperone levels should increase as clients proliferate. Indeed, there is a clear rationale for this mechanism in the case of HSP90, as its transcription is activated by the factor HSF1, which undergoes induction by increased accumulation of unfolded proteins 34 . However, the CDC37 promoter is devoid of canonical HSF1 binding elements and does not respond to HSF1 activation. A further clue that warrants exploration is that CDC37 is overexpressed in prostate cancer and such cancers are induced by the forced expression of CDC37 (Refs 6, 14) . As AR is one of the rare non-kinase clients for CDC37, and is essential for proliferation and differentiation of prostatic epithelium, a role for AR would fit the profile 6 . Recent studies address the feasibility of targeting CDC37 in prostate carcinoma 15, 35 . Depletion of CDC37 in prostate cancer cell lines by RNA interference techniques leads to permanent growth inhibition both in androgen-dependent and androgen-independent cell lines 35 . Growth inhibition was correlated with decreased signalling through the anabolic extracellular signal-regulated kinase (ERK) and Akt kinase cascades as well as reduced AR-dependent transcriptional signalling 35 ( fIG. 2) . In addition, CDC37 targeting inhibits HSF1 activity and HSP70 expression, components of a common resistance pathway that mediates insensitivity to therapeutics such as HSP90 inhibitors and proteasomal targeting agents 35, 36 (fIG. 2) . Inactivation of CDC37 may thus decrease cell survival through a range of pathways, permitting effective inhibition of anabolic signalling and breaking resistance to cytotoxic therapy. It is significant that the consequences of CDC37 depletion and HSP90 inhibition are divergent at the molecular level, with HSP90 inactivation triggering degradation of the abandoned clients while CDC37 depletion does not 35 (fIG. 3) .
CDC37 knockdown instead causes profound inhibition of the activities of multiple kinase cascades and loss of the transcriptional activity of AR 35 . These data suggest intrinsic differences in the relationships between HSP90 and CDC37 and their clients that become unmasked during therapy. CDC37 is evidently not essential for the intracellular survival of its clients, whereas functional HSP90 is required to prevent degradation 37 ( fIG. 3) . However, in order for protein kinases to transfer phosphate to their substrates or for AR to interact productively with its ligand, CDC37 is indispensable. Further underlining the contrasting mechanisms of HSP90-and CDC37-dependent prostate cancer growth, functional inhibition of both proteins in tumour cells is supra-additive 35 . The question of independent, non-HSP90-requiring interactions for CDC37 observed in recent studies also arises 20 . Recent work also shows that depletion of another HSP90 co-chaperone AHA1, (also known as AHSA1), leads to a similar reduction in activity of HSP90 client kinases without marked increases in degradation of such proteins. These findings suggest that degradation of clients may require direct interaction between drugged, inactive HSP90 and its bound clients and cannot be mimicked by the inactivation of co-chaperones 38 . Targeting HSP90 co-chaperones might therefore lead to radically different consequences compared with the direct inhibition of HSP90. Future strategies for CDC37 drug design and selection would probably aim at the inhibition of either the CDC37-client interaction or CDC37-HSP90 association (fIG. 1) . Indeed, recent studies using the . These natural plant products cause pleiotropic changes in cancer cells and can lead to tumour regression 39 . However, the cellular responses to celastrol resemble those provoked by HSP90 inhibitors, and include client protein destruction and HSF1 activation and might not provide a radical departure from current treatments. Further studies might concentrate on agents with more novel mechanisms of action such as CDC37-client interaction.
In conclusion, inhibition of CDC37 activity is a promising new approach to the treatment of cancer owing to its multi-targeting nature, the increased expression of CDC37 in dividing cells and the ability of CDC37 depletion to arrest growth in both AR + and AR -prostate cancer. CDC37 targeting also has the potential ability to deter the evolution of new traits that depend on kinase mutation and such a block on adaptation might limit the ability of tumours to respond to therapy and a deteriorating microenvironment. Such effects are proposed to occur in tumours treated with HSP90-targeting drugs 1 . As to the ultimate selectivity of CDC37 inhibition for treating malignant cells, this chaperone is not expressed in quiescent cells but appears necessary for the growth of normal epithelial cells. Therefore, treating prostate cancer through the inhibition of CDC37 might involve sacrificing this non-essential population 15 . However, this drawback would not differ markedly from that of current therapies used to treat prostate cancer, which also focus on eradicating normal prostate tissue as well as cancer. one concern with this therapy could be the unknown potential for effects on other normally proliferating epithelium, including that in the gastrointestinal tract and skin.
Future directions
More remains to be learned regarding the oncogenic role of CDC37 and its utility as a target for cancer therapy. Thus we remain uncertain of the full extent of types and stages of cancer mediated by CDC37 overexpression and such a gap in knowledge will hopefully be rectified in subsequent studies. Future studies will also ask, by which molecular mechanism(s) does CDC37 become overexpressed during tumour progression? Promising approaches to CDC37 targeting of malignant tissues that will probably be explored include pharmacological disruption of CDC37-client interactions and modulation of phosphorylation of the key residue S13 within the client-interaction domain of CDC37. . Kinases (rectangles) interact with both HsP90 (squares) and CDC37 (circles). However, whereas pharmacological inhibition of HsP90 (red rectangle) leads to client degradation, depletion of CDC37 (red circle) causes a block to client maturation and activity that does not involve such extensive client destruction. These molecular differences result in alternative pathways of malignant cell inactivation, with the consequence that therapies targeting these two proteins act synergistically, and produce supra-additive responses to treatment.
